Last updated on July 2014

The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Breast Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    Patients with newly diagnosed stage I-IV breast cancer (tumor size
    2cm in imaging examinations) who are scheduled to start systemic therapy.
    Patients must have histological diagnosis of invasive breast cancer.
    Extent of disease will be determined by physical examination and conventional
    radiological studies.
    Must be age 18 or older.
    ECOG performance status 0-2.
    Patients with history of prior malignancies must be disease-free for at least 5 years
    of study entry.
    Normal hematological function: WBC > 3000/ul, absolute neutrophil count > 1500/ul,
    platelets > 100,000/ul, and Hgb > 10 gms (transfusion to achieve Hgb > 10 gms is
    acceptable).
    Serum total bilirubin < 1.5 mg/dl and SGPT < 1.5 X normal.
    Adequate kidney function (creatinine < 1.5 mg/dL).

You may not be eligible for this study if the following are true:

  • Patients who received previous chemotherapy for the newly diagnosed breast cancer.
    No evidence of primary breast lesion (e.g. T0, Tx).
    Pregnant women or sexually active women of childbearing potential who are not
    practicing adequate contraception are excluded.
    Patients with myocardial infarction within 6 months of study entry; unstable angina
    pectoris; uncontrolled congestive heart failure; uncontrolled arrhythmia are
    excluded.
    Patients with history of hypersensitivity/allergy to Chitosan/Chitin related
    hellfish foods.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.